Efficacy and safety of Yifei Sanjie Recipe in the treatment of chemotherapy-related cancer-related fatigue in patients with non-small cell lung cancer: a N-of -1 multicenter randomized controlled trial

The First Affiliated Hospital of Guangzhou University of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. Patients with non-small cell lung cancer diagnosed by pathology or cytology;
•2. Meet the diagnostic criteria for cancer-related fatigue;
•3. The estimated survival time is more than 3 months, PS<=2, aged 18 to 80 years;
•4. Patients who are not suitable for targeted drug therapy;
•5. According to the guidelines, patients need to receive platinum-containing dual-drug-based chemotherapy, including AP (pemetrexed + cisplatin/carboplatin), TP (paclitaxel + cisplatin/carboplatin), DP (docetaxel) + Cisplatin/carboplatin), GP (gemcitabine + cisplatin/carboplatin); can be combined with anti-vascular drugs and immune checkpoint inhibitors;
•6. Those who voluntarily accept the treatment of this program, can adhere to the follow-up visit as prescribed by the doctor and have good compliance.

•1. Any situation that may hinder the subject from completing the clinical trial process, including but not limited to serious, difficult to control organic disease or infection, unstable angina, congestive heart failure, etc.; hypothyroidism has not been controlled;
•2. Severe liver and kidney dysfunction (serum creatinine >= 1.5 ULN; ALT or AST >= 5 ULN; bilirubin >= 1.5 ULN);
•3. Patients with neurological or mental disorders who are symptomatic and difficult to control, and others who cannot complete the questionnaire independently or assist by others.

发起方

The First Affiliated Hospital of Guangzhou University of Chinese Medicine